secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001193125-24-069123
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Akebia CFO Ellen Snow to depart March 22; CEO John Butler named interim principal financial officer
--------------------------------------------------------------------------------

- CFO Ellen Snow and company mutually agree on transition; effective March 22, 2024.
- CEO John Butler will serve as interim principal financial officer starting Transition Date.
- Separation agreement provides 12 months base salary, COBRA premium reimbursement, continued equity vesting.
- Severance conditioned on general release of claims and compliance with non-compete and non-solicitation terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000119312524069123/0001193125-24-069123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000119312524069123/d650653d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-069123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer